ATI-450

DRUG5 trials

Sponsors

Aclaris Therapeutics, Inc., University of Kansas Medical Center

Conditions

Covid19Cryopyrin-Associated Periodic SyndromeHidradenitis SuppurativaPsoriatic ArthritisRheumatoid Arthritis

Phase 2

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

CompletedNCT04247815

Aclaris Therapeutics, Inc.Rheumatoid Arthritis

Start: 2020-03-16End: 2021-02-04Updated: 2023-03-29

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

CompletedNCT04481685

University of Kansas Medical CenterCovid19

Start: 2020-07-20End: 2021-06-01Updated: 2025-06-04

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

TerminatedNCT04524858

Aclaris Therapeutics, Inc.Cryopyrin-Associated Periodic Syndrome

Start: 2020-10-23End: 2021-02-25Updated: 2023-09-21

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

CompletedNCT05216224

Aclaris Therapeutics, Inc.Hidradenitis Suppurativa

Start: 2021-12-29End: 2023-01-24Updated: 2026-01-07

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

TerminatedNCT05511519

Aclaris Therapeutics, Inc.Psoriatic Arthritis

Start: 2022-07-12End: 2024-01-03Updated: 2024-11-27

Related Papers

A Phase IIa, Double-Blinded, Randomized Placebo-Controlled Trial of MAPKAPK2 Inhibition by ATI-450 in Treatment of Moderate-Severe COVID-19 Pneumonia

2021-05-01